Stockreport

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

Neurogene Inc.  (NGNE) 
PDF Expanded Phase 1/2 gene therapy trial for Rett syndrome to inform future registrational study design; Company remains on track to share interim clinical data in 4Q:24Str [Read more]